Spike Health Rewards R & D Investment
Release time:
2020-08-14
Peak Health Won R & D Investment Award
News from our newspaper 10# July 11 , Peak Health Technology Company received 10.43 Yuan 2016 Enterprise R & D Investment Award from Wucheng District Finance Bureau of Jinhua City.
Enterprise R & D investment awards are based on the relevant spirit and requirements of the "Several Opinions of the People's Government of Wucheng District on Deepening the Implementation of the Innovation-Driven Development Strategy and Vigorously Promoting Mass Entrepreneurship and Innovation" and the "Management Measures for Special Financial Funds in Wucheng District, Jinhua City", The Wucheng District Science and Technology Bureau organizes the declaration, enterprises with 2016 R & D funds invested in 100 -300 (including 100 and 300 ) will be given 5% R & D funds subsidy. The award requires the reporting enterprise to have a sound research and development project management system and financial accounting system, the implementation of special account management of research and development costs, to carry out multiple research and development activities according to different research and development projects, respectively, the amount of research and development costs, and research and development projects by the enterprise independent project. After preliminary examination, the reward for peak health declaration was entrusted by the government department to conduct a special audit, and the reward amount of 10.43 yuan was finally approved. Other projects awarded by Wucheng District Enterprise Science and Technology Innovation Funds in 2016 are also being declared.
At present, Jianfeng Health is already a key scientific and technological innovation enterprise contacted by Wucheng District Science and Technology Bureau. Through the establishment of a relatively complete product development management system and research and development procedures, new product development, testing, improvement and testing are carried out. R & D personnel have high comprehensive quality, strong development ability, have received systematic professional training, and realize technological upgrading through independent innovation, integrated innovation, introduction, digestion, absorption and re-innovation. Peak Health has always insisted that the annual R & D expenditure investment is not less than the year's sales revenue of 5% , and independent accounting of R & D expenditure, in order to protect the company's R & D project market research, product development, the purchase of R & D equipment and other aspects of demand. The research and development department is currently carrying out two projects, namely, "pilot-scale process research on extracting natural high-efficiency antioxidant ergothioneine from mushrooms" and "industrialization technology research on extracting resveratrol and its oligomers from grapevines", which aim to carry out industrialization research using waste materials, and have received the attention of Jinhua and Wucheng science and technology bureaus, and have signed contracts for science and technology projects. (Xu Feng)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page